Megan Baldwin, PhD, Managing Director and CEO of Opthea, gives an update on OPT-302, a soluble receptor consisting of the first three extracellular domains of human VEGFR-3 linked to the Fc region of hIgG1. Baldwin explains how OPT-302 potently and specifically blocks VEGF-C and VEGF-D from binding and activating VEGFR-2 and VEGFR-3, making it a useful tool in the battle against Wet AMD. The company is conducting clinical trials in the US and is considering developing treatments of Wet AMD.
Dr. Megan Baldwin is CEO/Managing Director of Circadian Technologies (Opthea) and has over 19 years of experience in preclinical and clinical development of therapies for cancer and eye diseases. Dr. Baldwin joined Circadian in 2008 and since then has held various positions.